Perhaps the most remarkable thing about the building is “Amtagvi”. Amtagvi What has led to promising drugs in the treatment of solid cancers is that it is “live”, meaning that it is taken from living cells that are protected by the t -immune system when it fights against a malignant tumor.
The idea of this drug is easy to simplify. When a cancerous tumor appears in the body, the immune system tries to fight it and secretes cells that aim to attack these malignant cells. T lymphocytes are considered to be the most prominent part of the immune system against cancer, as they specifically go to and attack cancer cells, hoping to “eat” them and get rid of them. the malignant tumor. Often, T cells and other immune components do not attack the cancer, so it spreads and kills the body.
The failure of the body becomes a weapon in the hands of science
According to a long report published by the website “Science Live.org” on the scientific development mentioned above, American scientists from the company “Lovance Biotherapeutics” were working Lovance Biotherapeutics To take these cells and multiply them to number in the billions, before re-injecting them into people. They added a protective component, “interleukin 2.” Interleukin 2which enhances the function of immune T cells.
Live immune cell therapy is called TIL. TO Summary for the phrase Tumor infiltration therapy To show that it is up to the immune cells that people with cancer attack the malignant cells.
So far, Amtagvi has achieved good results. It has passed test stages directly in laboratory vessels, where it is mixed with cancer cells and its effectiveness against them is monitored. After that, this drug passed the testing stage on laboratory animals.
Last February, the US Food and Drug Administration approved the drug Amtagvi, with the scientific name Levelucil. Lifileucil As a drug against solid cancers, after passing the level of tests directly on people suffering from solid malignant tumors such as those affecting the lung, bone, prostate and others. [ولا يشمل ذلك مثلاً، سرطانات الدم]. Solid cancers make up about 90 percent of new cancer cases in the world, and are estimated to kill more than half a million Americans this year.
Amazing successes, but … let’s cross our fingers
A few weeks ago, the conference of the American Society of Clinical Cancer was observed American Society of Clinical Oncology A detailed presentation of the good results achieved with the drug “Amtagvi”.
The record of these results includes that it was given to 73 people suffering from solid cancers, as part of a clinical trial investigated by the Food and Drug Administration, and it caused atrophy in am tumors 23 of them (about a third), including. three cases were completely cured.
In a larger trial, Amtagvi was given to 153 people with solid tumors, and it gave positive results in 48 people, half of whom were still alive until 2023, when the trial ended.
The numbers may seem small, but they are still full of positive signs.
Finally, the company that made Amtagvi announced that they are currently seeking approval from the European group to the US Food and Drug Administration, as is the case for similar groups in Canada, the United Kingdom and Australia.
Do you believe the promises of Amtagvi and will it succeed in eliminating the hopelessness of cancer treatment and recovery?
Let’s wait for Willner.
2024-08-24 06:42:00
#living #drug #treat #cancer #approved #America #awaiting #reality #promises
